Dott. Dario Apuzzo, medico presidente AIRO: l’Ossigeno-Ozono Terapia agisce su Covid-19 direttamente.

Dott. Dario Apuzzo, medico  presidente AIRO: l’Ossigeno-Ozono Terapia agisce su Covid-19 direttamente.

 by Giulio de Nicolais

Buongiorno Dott. Apuzzo, ci parli di lei e della sua attività.

Sono medico fisiatra e presidente AIRO, Accademia Internazionale Ricerca in Ossigeno-Ozono Terapia. Mi occupo di Ossigeno-Ozono Terapia da 26 anni e conoscendo bene gli effetti di questa terapia, ho messo a punto con il mio gruppo, nonché con ISCO3, International Scientific Committee of Ozone Therapy, di cui rappresento l’unico membro italiano, un protocollo per il trattamento del Covid-19. La voglia e la convinzione di poter aiutare molte persone affette dal Corona virus ci ha portato a chiedere l’autorizzazione a procedere con la sperimentazione (a costo zero) in diversi ospedali del Lazio, ma al momento non siamo ancora riusciti ad averla. Un vero peccato, perché si tratta di una terapia naturale, senza effetti collaterali e senza controindicazioni.
 
Qual è il “razionale” della terapia, perchè l’Ossigeno-Ozono Terapia potrebbe contrastare il Covid-19? 
 
L’Ossigeno-Ozono Terapia agirebbe sul virus sia direttamente, inattivandolo quando si trova nel sangue, fuori dalle cellule, impedendogli in tal modo di attaccarsi e penetrare nelle cellule, sia indirettamente, modulando la risposta immunitaria dell’organismo. L’azione fluidificante dell’Ossigeno-Ozono sul sangue poi, potendo in un certo senso simulare l’azione dell’eparina, protegge l’organismo dalla formazione di coaguli intravascolari, che, giunti ai polmoni, possono rappresentare una delle cause principali dell’insufficienza respiratoria, per la quale quindi più che la ventilazione sarebbe importante la risoluzione dei coaguli stessi; d’altro canto, l’apporto di ossigeno direttamente nel sangue consentirebbe di bypassare almeno in parte l’apparato respiratorio, piuttosto compromesso dal virus, ossigenando così l’intero organismo. Molto importante  anche l’azione antiinfiammatoria della miscela gassosa, che contribuirebbe alla risoluzione dei sintomi.
 
Grazie Dott. Apuzzo per averci concesso questa intervista su una tematica così attuale.
 
 

Segue una corposa bibliografia scientifica sull’argomento.

 

Riferimenti

  
1.    WHO. Responding to community spread of COVID-19 Interim guidance 7 March 2020. WHO  file:///C:/Users/USER-PC/Downloads/WHO-COVID-19-Community_Transmission-2020.1-eng.pdf) (Acessed on 12/03/2020)2020.
 
2.    Ghebreyesus T. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020.  https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (Acessed on 12/03/2020)2020.
 
3.    Ghebreyesus T. WHO Director-General's opening remarks at the media briefing on COVID-19 - 12 March 2020.  https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---12-march-2020) (Acesses on 12/03/2020)2020.
 
4.    Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. Feb 17 2020:105924.
 
5.    WHO. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on March 3, 2020). 2020.
 
6.    Li X, Zai J, Zhao Q, et al. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. Feb 27 2020.
 
7.    Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. Feb 21 2020;81:104260.
 
8.    Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. Int J Occup Environ Med. Feb 5 2020;11(2):65-71.
 
9.    Xiong Y, Sun D, Liu Y, et al. Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes. Invest Radiol. Mar 3 2020.
 
10.  Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. Mar 2020;30(3):269-271.
 
11.  WHO. World Health Organization. International Clinical Trials Registry Platform. http://apps.who.int/trialsearch/ [Accessed on 07/03/2020]. 2020.
 
12.  NIH. U.S. National Library of Medicine. Clinical Trials.gov https://www.clinicaltrials.gov/ [Accessed on 07/03/2020]. 2020.
 
13.  Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. Jun 2004;203(2):622-630.
 
14.  Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. Mar 4 2020.
 
15.  Deng SQ, Peng HJ. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med. Feb 20 2020;9(2).
 
16.  Hudson JB, Sharma M, Vimalanathan S. Development of a Practical Method for Using Ozone Gas as a Virus Decontaminating Agent. Ozone: Science & Engineering. 2009;31:216-223.
 
17.  Guangjian N, Hongzhi Y. Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19). ChiCTR2000030165. Academy of Medical Engineering and Translational Medicine, Tianjin University. 2020-02-24. http://www.chictr.org.cn/showproj.aspx?proj=49947 (Accessed 8/03/2020). . 2020.
 
18.  Linlin H, Xiangdong C. A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19). ChiCTR2000030006. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. 2020-02-19. http://www.chictr.org.cn/showproj.aspx?proj=49737 (Accessed 8/03/2020). . 2020.
 
19.  Huiling H, Tong X. A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19). ChiCTR2000030102. Tianjin Huanhu Hospita. 2020-02-23. http://www.chictr.org.cn/showproj.aspx?proj=49747 (Accessed 8/03/2020). 2020.
 
20.  Soodmand M. A survey of the effect of ozonated water mouthwash on oral health and incidence of ventilator-associated pneumonia in patients connected to mechanical ventilation in intensive care units - A randomized clinical trial. IRCT20180213038720N2. Registration date: 2019-12-18, 1398/09/27 https://en.irct.ir/trial/41951 (Accessed 8/03/2020). . 2019.
 
21.  WHO. World Health Organization. Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts. Updated February 4, 2020. https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts (Accessed on March 8, 2020). 2020.
 
22.  CDC. Centers for Disease Control and Prevention. Interim guidance for persons who may have 2019 Novel Coronavirus (2019-nCoV) to prevent spread in homes and residential communities. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html#First_heading (Accessed on March 08, 2020). 2020.
 
23.  WHO. World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. January 25, 2020. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125 (Accessed on March 08, 2020). 2020.
 
24.  CDC. Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) or Patients Under Investigation for 2019-nCoV in Healthcare Settings. February 3, 2020. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html (Accessed on March 08, 2020). 2020.
 
25.  Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA. Mar 4 2020.
 
26.  EPA. United States Environmental Protection Agency. EPA’s Registered Antimicrobial Products for Use Against Novel Coronavirus SARS-CoV-2, the Cause of COVID-19. 03/03/2020. https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2 (Accessed 8/03/2020). 2020.
 
27.  Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect. Mar 2016;92(3):235-250.
 
28.  Roy D, Wong PK, Engelbrecht RS, Chian ES. Mechanism of enteroviral inactivation by ozone. Appl Environ Microbiol. Mar 1981;41(3):718-723.
 
29.  Murray BK, Ohmine S, Tomer DP, et al. Virion disruption by ozone-mediated reactive oxygen species. J Virol Methods. Oct 2008;153(1):74-77.
 
30.  Lin YC, Wu SC. Effects of ozone exposure on inactivation of intra- and extracellular enterovirus 71. Antiviral Res. Jul 2006;70(3):147-153.
 
31.  Kekez MM, Sattar SA. A new ozone-based method for virus inactivation: preliminary study. Phys Med Biol. Nov 1997;42(11):2027-2039.
 
32.  Barker J, Vipond IB, Bloomfield SF. Effects of cleaning and disinfection in reducing the spread of Norovirus contamination via environmental surfaces. J Hosp Infect. Sep 2004;58(1):42-49.
 
33.  Hudson JB, Sharma M, Petric M. Inactivation of Norovirus by ozone gas in conditions relevant to healthcare. J Hosp Infect. May 2007;66(1):40-45.
 
34.  OSAHA. Occupational Safety and Health Administration. Occupational Safety and Health Standards. Toxic and Hazardous Substances. 1910.1000 TABLE Z-1  Limits for Air Contaminants. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1000TABLEZ1 (Accessed 8/03/2020). 2020.
 
35.  Dyas A, Boughton BJ, Das BC. Ozone killing action against bacterial and fungal species; microbiological testing of a domestic ozone generator. J Clin Pathol. Oct 1983;36(10):1102-1104.
 
36.  Foarde KK, VanOsdell DW, Steiber RS. Investigation of Gas-Phase Ozone as a Potential Biocide. Applied Occupational and Environmental Hygiene 1997;12(8):535-542.
 
37.  Lemon SM. SARS: Clearing the air. In: Knobler S, Mahmoud A, Lemon S, Mack A, Sivitz L, Oberholtzer K, eds. Learning from SARS: Preparing for the Next Disease Outbreak: Workshop Summary. Washington (DC): National Academies Press; 2004:376.
 
38.  Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. Jul 2009;29(4):646-682.
 
39.  ISCO3. First Aids in Ozone Therapy. (Inhalatory exposition and accidental over dose). 2015; 16. Available at: www.isco3.org. Accessed March 8, 2020.
 
40.  Cardoso CC, Fiorini JE, Ferriera LR, Gurjao JW, Amaral LA. Disinfection of hospital laundry using ozone: microbiological evaluation. Infect Control Hosp Epidemiol. Apr 2000;21(4):248.
 
41.  Wang J, Shih Y, Wang PY, Yu YH, Su JF, Huang CP. Hazardous waste treatment technologies. Water Environ Res. Oct 2019;91(10):1177-1198.
 
42.  Wang H, Sikora P, Rutgersson C, et al. Differential removal of human pathogenic viruses from sewage by conventional and ozone treatments. Int J Hyg Environ Health. Apr 2018;221(3):479-488.
 
43.  Gottschalk C, Libra JA, Saupe A. Ozonation of Water and Waste Water: A Practical Guide to Understanding Ozone and its Application: ohn Wiley & Sons; 2008.
 
44.  Cardis D, Tapp C, DeBrum M, Rice RG. Ozone in the Laundry Industry-Practical Experiences in the United Kingdom. Ozone: Sci. Eng. 2007;29:85-89.
 
45.  Shin GA, Sobsey MD. Reduction of Norwalk virus, poliovirus 1, and bacteriophage MS2 by ozone disinfection of water. Appl Environ Microbiol. Jul 2003;69(7):3975-3978.
 
46.  Kim JG, Yousef AE, Dave S. Application of ozone for enhancing the microbiological safety and quality of foods: a review. J Food Prot. Sep 1999;62(9):1071-1087.
 
47.  Naito S, Takahara H. Ozone Contribution in Food Industry in Japan. Ozone Sci. Eng. 2006;28:425–429.
 
48.  Wolf C, von Gunten U, Kohn T. Kinetics of Inactivation of Waterborne Enteric Viruses by Ozone. Environ Sci Technol. Feb 20 2018;52(4):2170-2177.
 
49.  Bocci V. Ozone: A new medical drug. Netherlands: Springer; 2011.
 
50.  ISCO3. Non-recommended routes of application in ozone therapy ISCO3/LEG/00/10. 2017:13. www.isco3.org.
 
51.  Burgassi S, Zanardi I, Travagli V, Montomoli E, Bocci V. How much ozone bactericidal activity is compromised by plasma components? J Appl Microbiol. May 2009;106(5):1715-1721.
 
52.  Bocci V, Paulesu L. Studies on the biological effects of ozone 1. Induction of interferon gamma on human leucocytes. Haematologica. Nov-Dec 1990;75(6):510-515.
 
53.  Martinez-Sanchez G. Mechanisms of action of O3.  Genomic pathways. Ozone Therapy Global Journal. 2019 2019;9(1):21-22.
 
54.  Delgado-Roche L, Riera-Romo M, Mesta F, Hernández-Matos Y, Barrios JM, Martínez-Sánchez G. Medical Ozone Promotes Nrf2 Phosphorylation  Reducing Oxidative Stress And Proinflammatory  Cytokines In Multiple Sclerosis Patients. Rev Esp Ozonoterapia. 2018 2018;8(2 Supp 1):48-49.
 
55.  Martinez-Sanchez G, Delgado-Roche L. Up-date on the mechanisms of action of ozone through the  modification of cellular signaling pathways. Role of Nrf2 and  NFkb. Rev Esp Ozonoterapia. 2017 2017;7(2):17-18.
 
56.  Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front Chem. 2015;3:4.
 
57.  Re L, Martinez-Sanchez G, Bordicchia M, et al. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur J Pharmacol. Nov 5 2014;742:158-162.
 
58.  Pecorelli A, Bocci V, Acquaviva A, et al. NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicol Appl Pharmacol. Feb 15 2013;267(1):30-40.
 
59.  Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. Apr 18 2008;133(2):235-249.
 
60.  Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. Toxicol In Vitro. Feb 2005;19(1):55-61.
 
61.  Lintas G, Liboni W, Simonetti V, et al. Long-term cerebrovascular reactivity mediated by ozone autohemotherapy: a NIRS study. Paper presented at: Terzo Congresso del Gruppo Nazionale di Bioingegneria; 2012, 2012.
 
62.  Zaky S, Fouad EA, Kotb HIM. The effect of rectal ozone on the portal vein oxygenation and pharmacokinetics of propranolol in liver cirrhosis (a preliminary human study). British Journal of Clinical Pharmacology. Mar 2011 2011;71(3):411-415.
 
63.  Guan YJ, Tang XP, Yin CB, Yi ZQ. [Study on the damage of liver in patients with SARS]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. May 2004;16(5):267-270.
 
64.  Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res. Jul 2017;143:142-150.
 
65.  Khan G. A novel coronavirus capable of lethal human infections: an emerging picture. Virol J. Feb 28 2013;10:66.
 
66.  Simonetti V, Quagliariello V, Franzini M, Iaffaioli RV, Maurea N, Valdenassi L. Ozone Exerts Cytoprotective and Anti-Inflammatory Effects in Cardiomyocytes and Skin Fibroblasts after Incubation with Doxorubicin. Evid Based Complement Alternat Med. 2019;2019:2169103.
 
67.  Delgado-Roche L, Hernandez-Matos Y, Medina EA, Morejon DA, Gonzalez MR, Martinez-Sanchez G. Ozone-Oxidative Preconditioning Prevents Doxorubicin-induced Cardiotoxicity in Sprague-Dawley Rats. Sultan Qaboos Univ Med J. Aug 2014;14(3):e342-348.
 
68.  Adali Y, Eroglu HA, Makav M, Guvendi GF. Efficacy of Ozone and Selenium Therapy for Alcoholic Liver Injury: An Experimental Model. In Vivo. May-Jun 2019;33(3):763-769.
 
69.  Tezcan AH, Ozturk O, Ustebay S, Adali Y, Yagmurdur H. The beneficial effects of ozone therapy in acetaminophen-induced hepatotoxicity in mice. Pharmacol Rep. Apr 2018;70(2):340-345.
 
70.  Kaldirim U, Uysal B, Yuksel R, et al. Ozone therapy ameliorates paraquat-induced lung injury in rats. Exp Biol Med (Maywood). Dec 2014;239(12):1699-1704.
 
71.  Wang L, Chen H, Liu XH, et al. Ozone oxidative preconditioning inhibits renal fibrosis induced by ischemia and reperfusion injury in rats. Exp Ther Med. Dec 2014;8(6):1764-1768.
 
72.  Bocci V, Zanardi I, Travagli V. Ozonation of human HIV-infected plasmas for producing a global vaccine: How HIV-patients may help fight the HIV pandemia. Virulence. May-Jun 2010;1(3):215-217.
 
73.  Bocci V, Travagli V, Zanardi I. The failure of HIV vaccines: a new autovaccine may overcome some problems. Medical Hypotheses. Jun 2009 2009;72(6):662-664.
 
74.  Schwartz-Tapia A, Martínez-Sánchez G, Sabah F, et al. Madrid Declaration on Ozone Therapy. . ISCO3. 2015:50.
 
75.  Peretiagyn SP, Struchkov АА, eretiagyn NC, Кulechina  NВ, Inventors; 2289413, assignee. Ozonization Method of Saline Solution2006.
 
76.  Shmakova IP, Nazarov EI. Methods of application of ozone in medicine (guidelines). 2004.
 
77.  Maslennikov OV, Kontorshikova CN, Gribkova IA. Ozone therapy in Practice. Health Manual, Ministry Health Service of The Russian Federation The State Medical Academy Of Nizhny Novgorod, Russia. http://www.absoluteozone.com/assets/ozone_therapy_in_practice.pdf. 1 ed2008.
 
78.  Razumovskii SD, Konstantinova ML, Grinevich TV, Korovina GV, Zaitsev VY. Mechanism and kinetics of the reaction of ozone with sodium chloride in aqueous solutions. Kinetics and Catalysis. 2010;51(4):492-496.
 
79.  Boyarinov GA, Gordetsov AS, Peretyagin SP, Matusyak KS, Ovchinnikov YV, Boyarinova LV. The analysis of interaction of ozone and sodium chloride in Aqueous solution. Rev Esp de Ozonoterapia. 2016;6(Supp 1):77.
 
80.  Gorbunov SN, Korhouknov AE, Mozhaev MV, et al. [Structural-molecular transformations of water solutions of electrolytes under the influence of medical ozone]. Meditsinskii almanakh. 2013 2013(3):38-40.
 
81.  Boyarinov GA, Sokolov VV. Ozonized cardiopulmonary bypass (experimental justification and clinical results). Nizhny Novgorod,1999.
 
82.  Boyarinov GA, Monakhov AN, Medvedev AP, Chiginev VA, Beaver VM, Gamzaev AB. The effect of the ozonized cardioplegic solution on cardiodynamics during cardiac valve prostheses // In the book: Ozone in biology and medicine: Abstract. Doc. II Vseros. Scientific and practical confer. with international participation Nizhny Novgorod. Nizhny Novgorod1995.
 
83.  ISCO3 I. ISCO3/MET/00/01 Major  Autohemotherapy (AHTmayor).
 
84.  ISCO3. ISCO3/MET/00/02 Minor Autohemotherapy. isco3.org/ 2016
 
85.  ISCO3. Extracorporeal blood oxygenation-ozonation (EBOO) ISCO3/MET/00/22. 2016;1:9.
 
86.  Amatore D, Celestino I, Brundu S, et al. Glutathione increase by the n-butanoyl glutathione derivative (GSH-C4) inhibits viral replication and induces a predominant Th1 immune profile in old mice infected with influenza virus. FASEB Bioadv. May 2019;1(5):296-305.
17/04/2020
Share:


I NOSTRI SITI



Ultime interviste

© Copyright 2012-2020 DonnaDonna.eu - Privacy Policy - Cookie Policy
Realizzazione siti web